

Ref: CAGL/EQ/2023-24/102

October 21, 2023

To

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001
Scrip code: 541770

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex, Bandra (East)
Mumbai - 400051
Symbol: CREDITACC

Dear Sir/Madam,

Sub.: Newspaper Publication of Q2 FY24 Financial Results

Pursuant to Regulation 47(1)(b) of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the copies of newspaper publication of the Financial Results of the Company for the quarter and half year ended September 30, 2023, published today i.e. October 21, 2023, in Financial Express and Vishwavani (Kannada) newspapers.

Please take the same on record.

Thanking you,

Yours' Truly
For CreditAccess Grameen Limited

M. J. Mahadev Prakash
Company Secretary & Chief Compliance Officer

Encl.: As above

IMPORTANT
 Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

NORTH EASTERN ELECTRIC POWER CORPORATION LIMITED
 (A Government of India Enterprise)
 CIN : U40101ML1976GOI001658

NOTICE

Petition under Section 62 and 79(1) (a) of the Electricity Act, 2003 read with Chapter-V of the Central Electricity Regulatory Commission (Conduct of Business) Regulations, 1999 and Central Electricity Regulatory Commission (Terms and Conditions of Tariff) Regulations, 2019 has been filed before the Hon'ble Central Electricity Regulatory Commission for determination of tariff of Kameng Hydro Power Station (KaHPS) (4 X 150 = 600 MW) for the period from unit wise CODs to 31.03.2024. For details please refer to website: www.neepco.co.in

Dated: 19th October 2023
 Place: Shillong Head of Commercial Department

LIC MUTUAL FUND

LIC Mutual Fund Asset Management Limited
 (Investment Managers to LIC Mutual Fund)
 CIN No: U67190MH1994PLC077858

Registered Office: Industrial Assurance Bldg, 4th Floor, Opp. Churchgate Station, Mumbai - 400 020
 Tel. No.: 022-66016000, Toll Free No.: 1800 258 5678, Fax No.: 022-22835606
 Email: service LICMF@klintech.com • Website: www.licmf.com

Notice No. 48 of 2023-2024

DECLARATION OF DISTRIBUTION OF INCOME & CAPITAL UNDER THE SCHEMES, LIC MF AGGRESSIVE HYBRID FUND (FORMERLY KNOWN AS LIC MF EQUITY HYBRID FUND) AND LIC MF ELSS (FORMERLY KNOWN AS LIC MF TAX PLAN)

NOTICE is hereby given that LIC Mutual Fund Trustee Private Limited, the Trustee to LIC Mutual Fund has approved the declaration of Distribution of Income & Capital under Income Distribution cum Capital Withdrawal (IDCW) option(s) of the Schemes, LIC MF Aggressive Hybrid Fund and LIC MF ELSS, as under:

Name of the schemes	Face Value (₹ per unit)	IDCW Rate (₹ per unit)*	Record Date**	NAV as on October 19, 2023 (₹ per unit)
LIC MF Aggressive Hybrid Fund - Direct Plan - IDCW Option	10.00	0.10	25 th October 2023	16.5731
LIC MF Aggressive Hybrid Fund - Regular Plan - IDCW Option		0.10		14.2169
LIC MF ELSS - Direct Plan - IDCW Option		0.20		28.7977
LIC MF ELSS - Regular Plan - IDCW Option		0.20		24.4880

*The payout shall be reduced by the amount of applicable statutory levy.
 **Or the immediate next Business Day if that day is not a Business Day.

Pursuant to payment of IDCW, the NAV of the IDCW Option(s) of the schemes would fall to the extent of payout and statutory levy.

The above IDCW is subject to the availability of distributable surplus and may be lower to the extent of distributable surplus available on the Record Date.

In case the distributable surplus is less than the quantum of IDCW on the record date / ex-IDCW date, the entire available distributable surplus in the scheme / plan will be declared as IDCW.

IDCW will be paid to those Unitholders / Beneficial Owners whose names appear in the Register of Unit holders maintained by the Mutual Fund / statement of beneficial ownership maintained by the Depositories, as applicable, under the IDCW Option of the aforesaid plans of the Scheme as on the record date.

In view of individual nature of tax consequences, each investor is advised to consult his / her own professional financial / tax advisor.

Date : October 20, 2023
 Place: Mumbai

For LIC MUTUAL FUND ASSET MANAGEMENT LIMITED
 Sd/-
 Authorized Signatory

As part of Go-Green initiative, investors are encouraged to register/update their email ID and Mobile Number with us to support paper-less communication.
 Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

CREDITACCESS GRAMEEN LIMITED
 Regd. & Corp. Office: No. 49, 46th Cross, 8th Block, Jayanagar, (Next to Rajalakshmi Kalyana Mantap) Bengaluru KA-560070 IN
 Website : www.creditaccessgrameen.in
 CIN: L51216KA1991PLC053425

Unaudited Consolidated Financial Result for the Quarter and Half year ended September 30, 2023

Sl. No.	Particulars	(₹ in Crores)			
		Quarter ended	Half year ended	Quarter ended	Year ended
		Sept. 30, 2023	Sept. 30, 2023	Sept. 30, 2022	March 31, 2023
1	Total Income from Operations	1,247.59	2,418.32	814.31	3,550.79
2	Net Profit for the period before Tax, Exceptional and/or Extraordinary items	466.77	934.15	229.01	1,105.42
3	Net Profit for the period before Tax and after Exceptional and/or Extraordinary items	466.77	934.15	229.01	1,105.42
4	Net Profit for the period after Tax, Exceptional and/or Extraordinary items	347.04	695.51	175.15	826.06
5	Total Comprehensive Income for the period (Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	342.01	679.25	151.57	834.47
6	Paid-up Equity Share Capital	159.11	159.11	156.11	158.91
7	Reserves excluding Revaluation Reserves	3,154.40	3,154.40	2,153.51	2,469.47
8	Securities Premium Account	2,484.23	2,484.23	2,272.40	2,478.59
9	Net worth	5,797.74	5,797.74	4,582.02	5,106.97
10	Outstanding Redeemable Preference Shares	Nil	Nil	Nil	Nil
11	Debt Equity Ratio	3.05	3.05	2.69	3.19
12	Paid-up Debt Capital/Outstanding Debt	17,668.56	17,668.56	12,308.16	16,312.26
13	Earnings Per Share (Face value ₹10 per share) (for continuing and discontinued operations) - not annualized				
	- Basic (₹)	21.82	43.74	11.04	52.04
	- Diluted (₹)	21.69	43.51	10.98	51.82
14	Capital Redemption Reserve	Nil	Nil	Nil	Nil
15	Debt Service Coverage Ratio	Not Applicable	Not Applicable	Not Applicable	Not Applicable
16	Interest Service Coverage Ratio	Not Applicable	Not Applicable	Not Applicable	Not Applicable

Notes:

- The above financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their respective meetings held on October 20, 2023. The Joint Statutory Auditors have expressed an unmodified opinion on the both Standalone and Consolidated financial statements for the year.
- Standalone Total Income from operations: ₹ 1,247.59 Cr/- and ₹ 2,418.32 Cr/-; (b) Net profit before tax: ₹ 468.94 Cr/- and ₹ 934.15 Cr/-; and (c) Net profit after tax: ₹ 349.21 Cr/- and ₹ 695.51 Cr/- for the quarter and financial year ended respectively.
- The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited Financial Results are available on the websites of National Stock Exchange of India at www.nseindia.com/corporates, BSE Limited at www.bseindia.com/corporates and on the Company's website at www.creditaccessgrameen.in
- For the other line items referred in regulation 52(4) of the amended Listing Regulations, pertinent disclosures have been made to the Stock Exchange(s) and can be accessed through the website link given in point no.3 above.

For and on behalf of the Board of CreditAccess Grameen Limited
 Sd/-
 Udaya Kumar Hebbar
 Managing Director

Date: October 20, 2023
 Place: Bengaluru

glenmark
LIFE SCIENCES
Glenmark Life Sciences Limited

Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpath, Solapur-413 213, India.
 Corporate Office: 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai-400 099, India.
 Phone No.: +91 22 68297979; CIN: L74900PN2011PLC139963; Website: www.glenmarklifesciences.com; Email: complianceofficer@glenmarklifesciences.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2023
 (₹ in Millions, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Half Year Ended		Year ended
		30 Sep'23	30 Jun'23	30 Sep'22	30 Sep'23	30 Sep'22	31 Mar'23
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Income						
	Revenue from Operations	5,953.63	5,784.50	5,092.99	11,738.13	9,991.69	21,612.20
	Other Income	53.69	18.51	100.20	72.20	195.13	289.57
	Total Income	6,007.32	5,803.01	5,193.19	11,810.33	10,186.82	21,901.77
II	Expenses						
	Cost of Materials Consumed	2,694.04	2,982.13	2,682.07	5,676.17	5,294.57	10,985.25
	Changes in Inventories of Finished Goods and Work-in-Progress	36.76	(501.74)	(282.30)	(464.98)	(605.80)	(844.37)
	Employee Benefits Expense	667.14	481.32	473.69	1,148.46	878.25	1,801.80
	Finance Costs	3.99	3.96	1.33	7.95	2.68	5.47
	Depreciation and Amortisation Expense	131.29	126.12	99.35	257.41	198.14	420.94
	Other Expenses	884.85	891.18	783.14	1,776.03	1,520.60	3,246.59
	Total Expenses	4,418.07	3,982.97	3,757.28	8,401.04	7,288.44	15,615.68
III	Profit Before Tax (I-II)	1,589.25	1,820.04	1,435.91	3,409.29	2,898.38	6,286.09
IV	Tax Expenses						
	Current Tax	387.00	435.99	338.93	822.99	701.22	1,506.11
	Deferred Tax	14.88	29.55	28.20	44.43	41.05	110.37
	Total Tax Expenses	401.88	465.54	367.13	867.42	742.27	1,616.48
V	Profit for the Period / Year (III-IV)	1187.37	1,354.50	1,068.78	2,541.87	2,156.11	4,669.61
VI	Other Comprehensive Income (OCI)						
	Items that will not be reclassified to profit or loss						
	(a) Re-measurement of the post-employment benefit obligation	(25.98)	(0.97)	(6.31)	(26.95)	(5.92)	(3.88)
	(b) Income tax relating to the above	6.09	0.24	1.59	6.33	1.49	0.98
	Total Other Comprehensive Income / (Loss)	(19.89)	(0.73)	(4.72)	(20.62)	(4.43)	(2.90)
VII	Total Comprehensive Income for the Period / Year (V+VI)	1,167.48	1,353.77	1,064.06	2,521.25	2,151.68	4,666.71
VIII	Earnings per equity share (Face Value of ₹ 2/- each) (Not Annualised except for the year ended 31st March)						
	(a) Basic (in ₹)	9.69	11.05	8.72	20.75	17.60	38.11
	(b) Diluted (in ₹)	9.69	11.05	8.72	20.75	17.60	38.11
IX	Paid up Equity Share Capital, Equity Shares of ₹ 2/- each	245.05	245.05	245.05	245.05	245.05	245.05
X	Other Equity excluding Revaluation Reserve						21,137.02

See accompanying notes to the Financial Results

UNAUDITED BALANCE SHEET AS AT 30th SEPTEMBER, 2023
 (₹ in Millions)

Particulars	As at 30 th September 2023	As at 31 st March 2023	Particulars	Half Year Ended 30 th Sep'23	Half Year Ended 30 th Sep'22
	(Unaudited)	(Audited)		(Unaudited)	(Unaudited)
ASSETS			A. CASH FLOW FROM OPERATING ACTIVITIES		
Non-Current Assets			Profit Before Tax	3,409.29	2,898.38
Property, Plant and Equipment	7,657.32	7,748.90	Adjustments for:		
Capital Work-in-Progress	780.66	493.54	Loss / (Gain) on Sale / Discard of Property, Plant and Equipment (Net)	0.09	(1.97)
Intangible Assets	103.91	57.39	Depreciation and Amortisation Expense	257.41	198.14
Intangible Assets Under Development	68.49	122.62	Unrealised foreign exchange (gain) / loss	(10.43)	(47.30)
Financial Assets			Provision for Gratuity and Compensated Absence	39.49	10.59
(i) Investments	0.77	0.77	Provision for Doubtful Debts	20.33	-
(ii) Other Financial Assets	83.59	82.14	Shared Based Payment Expenses	14.05	18.68
Other Non-Current Assets	68.21	12.72	Interest Income	(74.91)	(73.88)
Total Non-Current Assets	8,762.95	8,518.08	Finance Costs	7.95	2.68
Current Assets			Operating Profit before Working Capital Changes	3,663.27	3,005.32
Inventories	6,695.12	6,041.71	Adjustments for Working Capital changes:		
Financial Assets			(Increase)/Decrease in Trade Receivables	(27.32)	(521.26)
(i) Trade Receivables	8,074.64	8,067.66	(Increase)/Decrease in Other Assets	(267.74)	(990.48)
(ii) Cash and Cash Equivalents	4,429.47	2,838.23	(Increase)/Decrease in Inventories	(653.41)	(1203.19)
(iii) Bank Balance other than Cash and Cash Equivalents	1.25	255.74	Increase/(Decrease) in Trade and Other Payables	108.25	1,070.21
(iv) Others Financial Assets	717.74	709.40	Cash Generated from Operations	2,823.05	1,360.60
Other Current Assets	848.60	590.65	Taxes Paid (Net of Refunds)	(660.87)	(607.31)
Total Current Assets	20,766.82	18,503.39	Net Cash Generated from Operating Activities	2,162.18	753.29
Total Assets	29,529.77	27,021.47	B. CASH FLOW FROM INVESTING ACTIVITIES		
EQUITY AND LIABILITIES			Non-Current Liabilities		
Equity			Financial Liabilities		
Equity Share Capital	245.05	245.05	(i) Lease Liabilities	159.93	170.92
Other Equity	23,672.32	21,137.02	Deferred Tax Liabilities (Net)	462.44	424.34
Total Equity	23,917.37	21,382.07	Total Non-Current Liabilities	622.37	595.26
Liabilities			Current Liabilities		
Non-Current Liabilities			Financial Liabilities		
Financial Liabilities			(i) Lease Liabilities	22.91	22.65
(i) Lease Liabilities	159.93	170.92	(ii) Trade Payables:		
Deferred Tax Liabilities (Net)	462.44	424.34	(a) Total Outstanding dues of Micro Enterprises & Small Enterprises	144.01	174.33
Total Non-Current Liabilities	622.37	595.26	(b) Total Outstanding dues of Other than Micro Enterprises & Small Enterprise	3,708.06	3,791.28
Current Liabilities			(iii) Other Financial Liabilities	577.51	532.96
Financial Liabilities			Other Current Liabilities	92.86	296.76
(i) Lease Liabilities	159.93	170.92	Provisions	211.78	155.38
Deferred Tax Liabilities (Net)	462.44	424.34	Income Tax Liabilities (Net)	232.90	70.78
Total Current Liabilities	4,990.03	5,044.14	Total Current Liabilities	4,990.03	5,044.14
Total Liabilities	5,612.40	5,639.40	Total Liabilities	5,612.40	5,639.40
Total Equity and Liabilities	29,529.77	27,021.47	Total Equity and Liabilities	29,529.77	27,021.47

Notes:

- The Financial Results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- The above Financial Results were reviewed by Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on October 20, 2023. These results have been subjected to limited review by statutory auditor who have issued an unmodified conclusion on the said results.
- Details of Utilisation of IPO Proceeds is as under:

Particulars	Estimated net proceeds as per Prospectus	Revised Net Proceeds	Utilised up to 30 Sep 23	Unutilised as on 30 Sep 23
Payment of outstanding purchase consideration to the Promoter for the spin-off of the API business from the Promoter into our Company pursuant to the Business Purchase Agreement dated October 9, 2018	8,000.00	8,000.00	8,000.00	-
Funding the capital expenditure requirements	1,527.64	1,527.64	1,283.71	243.93
General corporate purposes	576.75	494.40	494.40	-
Total	10,104.39	10,022.04	9,778.11	243.93

Unutilised amount as at September 30, 2023 were held in monitoring agency account and in deposits with scheduled commercial bank.

- The Company has identified only one segment i.e. Active Pharmaceutical Ingredient (API) as reporting segment based on the information reviewed by Chief Operating Decision Maker (CODM).
- As at September 30, 2023, pursuant to Employee Stock Option Plan 2021 8,77,712 options were outstanding, which upon exercise are convertible into equivalent number of equity share.
- The Board of Directors declared an interim dividend of ₹ 22.5/- per equity share of face value of each ₹ 2 each at its meeting held on October 9, 2023. The record date for the purpose of determining the entitlement for payment of interim dividend is fixed as October 17, 2023.
- Glenmark Pharmaceuticals Limited ("GPL"), the parent, along with the Company has entered into the share purchase agreement dated September 21, 2023 with Nirma Limited (the "Buyer") for the sale of 91,895,379 equity shares representing 75.00% of the current issued and paid-up equity share capital of the Company, by GPL to the Buyer, subject to the receipt of applicable approvals, customary conditions precedent, and other ancillary agreements (the "Transaction"), which are currently under process. Post the completion of the Transaction, GPL and the other member of the promoter group of the Company are proposed to be reclassified as public shareholders and the Buyer will be the new promoter of the Company.

For Glenmark Life Sciences Limited
 Yasir Rawjee
 Managing Director & CEO

Mumbai, October 20, 2023

